Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Chubb
US Department of Justice
UBS
QuintilesIMS
Citi
Johnson and Johnson
Queensland Health
Chinese Patent Office

Generated: September 20, 2018

DrugPatentWatch Database Preview

Pfizer Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for PFIZER PHARMS, and what generic alternatives to PFIZER PHARMS drugs are available?

PFIZER PHARMS has seven approved drugs.

There is one US patent protecting PFIZER PHARMS drugs.

Summary for Pfizer Pharms
US Patents:1
Tradenames:6
Ingredients:6
NDAs:7

Drugs and US Patents for Pfizer Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer Pharms ACCURETIC hydrochlorothiazide; quinapril hydrochloride TABLET;ORAL 020125-003 Dec 28, 1999 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer Pharms ACCUPRIL quinapril hydrochloride TABLET;ORAL 019885-004 Nov 19, 1991 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer Pharms ACCURETIC hydrochlorothiazide; quinapril hydrochloride TABLET;ORAL 020125-002 Dec 28, 1999 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer Pharms NEURONTIN gabapentin TABLET;ORAL 020882-001 Oct 9, 1998 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-002 Jan 29, 1997 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Pfizer Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-002 Dec 30, 1993 6,054,482*PED ➤ Try a Free Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997 5,602,133 ➤ Try a Free Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-001 Jan 29, 1997 6,011,049 ➤ Try a Free Trial
Pfizer Pharms ACCUPRIL quinapril hydrochloride TABLET;ORAL 019885-001 Nov 19, 1991 4,743,450*PED ➤ Try a Free Trial
Pfizer Pharms NEURONTIN gabapentin TABLET;ORAL 020882-001 Oct 9, 1998 6,054,482*PED ➤ Try a Free Trial
Pfizer Pharms REZULIN troglitazone TABLET;ORAL 020720-003 Aug 4, 1997 5,104,888 ➤ Try a Free Trial
Pfizer Pharms NEURONTIN gabapentin CAPSULE;ORAL 020235-003 Dec 30, 1993 4,024,175 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for PFIZER PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Sublingual Tablets 0.3 mg, 0.4 mg and 0.6 mg ➤ Subscribe 2005-10-19
➤ Subscribe Sublingual Tablets 0.6 mg ➤ Subscribe 2011-12-29

International Patents for Pfizer Pharms Drugs

Supplementary Protection Certificates for Pfizer Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0030 France ➤ Try a Free Trial PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
C/GB97/084 United Kingdom ➤ Try a Free Trial PRODUCT NAME: TROGLITAZONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK 10949/0277 19970729; UK 10949/0278 19970729; UK 10949/0279 19970729; UK 06384/0005 19970729; UK 06384/0006 19970729; UK 06384/0007 19970729
C/GB02/037 United Kingdom ➤ Try a Free Trial PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419
2011 00026 Denmark ➤ Try a Free Trial PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
00095 Netherlands ➤ Try a Free Trial PRODCUT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH VERDRAAGBAAR ZOUT, EN HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/02/213/001-010 20020419
C/GB99/008 United Kingdom ➤ Try a Free Trial PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
C0009 Belgium ➤ Try a Free Trial PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Citi
Deloitte
US Army
Accenture
UBS
Julphar
Argus Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.